**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 47100**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer**

Ntavatzikos A *et al.* Molecular profiling in CRC

**Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, Georgia Vourli, George Peros, Iordanis Papadopoulos, Ioannis Panayiotides, Anna Koumarianou**

**Anastasios Ntavatzikos, Anna Koumarianou,** Hematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Athens 12462, Greece

**Aris Spathis,** Department of Cytopathology, National and Kapodistrian University of Athens, Medical School, “ATTIKON” University Hospital, Athens 12462, Greece

**Paul Patapis, Nikolaos Machairas,** 3rd Department of Surgery, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Athens 12462, Greece

**Georgia Vourli,** Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece

**George Peros, Iordanis Papadopoulos,** Department of Surgery, Medical School, National and Kapodistrian University of Athens, Evgenideio Therapeutirio S.A., “I AGIA TRIAS”, Athens 11528, Greece

**Ioannis Panayiotides,** 2nd Department of Pathology, University of Athens, Medical School, “ATTIKON” University Hospital, Athens 12462, Greece

**ORCID number:** Anastasios Ntavatzikos (0000-0003-3343-3550); Aris Spathis (0000-0001-8867-3661); Paul Patapis (0000-0003-2349-769X); Nikolaos Machairas (0000-0003-3239-3905); Georgia Vourli (0000-0002-9727-2808); George Peros (0000-0001-7401-2811); Iordanis Papadopoulos (0000-0002-0620-3584); Ioannis Panayiotides (0000-0002-6394-117X); Anna Koumarianou (0000-0002-4159-2511).

**Author contributions:** Ntavatzikos A, Spathis A, Panayiotides I and Koumarianou A designed the research; Ntavatzikos A, Patapis P, Spathis A and Koumarianou A collected the data; Ntavatzikos A, Spathis A and Panayiotides I performed the research;Ntavatzikos A, Patapis P, Spathis A and Koumarianou A analyzed the data; Ntavatzikos A and Koumarianou A wrote the paper; Panayiotides I and Papadopoulos I offered technical or material support; Ntavatzikos A, Spathis A and Koumarianou A drafted the manuscript; all authors critically revised the manuscript for important intellectual content.

**Supported by** Kapodistrias, National and Kapodistrian University of Athens,No. 70/3/8006 (Pythagoras II, EPEAEK II, GSRT) and No. 70/3/9114; Spathis A was supported during data collection from No. 70/3/8462 [PENED – European Social Fund (75%) and the Greek Ministry of Development-GSRT (25%)].

**Institutional review board statement:** This study was reviewed and approved by the Institutional Review Board and Ethical Committee of University General Hospital Attikon, Athens, Greece.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Anastasios Ntavatzikos, MD, Research Scientist,** Hematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Rimini 1, Haidari, Athens 12462, Greece. [dmaal2@yahoo.gr](mailto:dmaal2@yahoo.gr)

**Telephone:** +30-210-5831687

**Fax:** +30-210-5326446

**Received:** March 14, 2019

**Peer-review started:** March 15, 2019

**First decision:** April 16, 2019

**Revised:** April 30, 2019

**Accepted:** June 12, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify CRC patients who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (*TYMS*) gene polymorphisms, *KRAS* and *BRAF* could be included in the molecular profile under consideration.

***AIM***

To investigate the association of *TYMS* gene polymorphisms, *KRAS* and *BRAF* mutations with survival of CRC patients treated with chemotherapy.

***METHODS***

A retrospective study studied formalin-fixed paraffin-embedded tissues (commonly known as FFPEs) of consecutive patients treated with adjuvant chemotherapy during January 2005-January 2007. FFPEs were analyzed with PCR for the detection of *TYMS* polymorphisms, mutated *KRAS* (m*KRAS*) and BRAF (m*BRAF*). Patients were classified into three groups (high, medium and low risk) according to 5’ UTR *TYMS* polymorphisms Similarly, based on 3’ UTR polymorphism ins/loss of heterozygosity (LOH), patients were allocated into two groups (high and low risk of relapse). Cox regression models examined the associated 5-year survival outcomes.

***RESULTS***

One hundred and thirty patients with early stage CRC (stage I-II: 55 patients; stage III 75 patients; colon: 70 patients; rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease-free survival and overall survival rate was 61.6% and 73.9% respectively. 5’ UTR polymorphisms of intermediate *TYMS* polymorphisms (2RG/3RG, 2RG/LOH, 3RC/LOH) were associated with lower risk for relapse [hazard ratio (HR) 0.320, *P* = 0.02 and HR 0.343, *P* = 0.013 respectively] and death (HR 0.368, *P* = 0.031 and HR 0.394, *P* = 0.029 respectively). The 3’ UTR polymorphism ins/LOH was independently associated with increased risk for disease recurrence (*P* = 0.001) and death (*P* = 0.005). m*BRAF* (3.8% of patients) was associated with increased risk of death (HR 4.500, *P* = 0.022) whereas m*KRAS* (39% of patients) was not.

***CONCLUSION***

Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type *BRAF* may identify patients at lower risk of relapse following adjuvant chemotherapy.

**Key words:** Colorectal neoplasms; Thymidylate synthase; Untranslated regions; Fluorouracil; *KRAS*; *BRAF*; Prognosis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is a need to identify patients with colorectal cancer (commonly known as CRC) who may benefit from adjuvant chemotherapy. We investigated the survival of 130 patients with stage II-III CRC treated with adjuvant chemotherapy based on thymidylate synthase (*TYMS*) gene polymorphisms, *KRAS* and *BRAF* status. We found that *TYMS* polymorphisms and *BRAF* status independently associate with survival outcomes. Prospective validation studies are required.

Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. *World J Gastrointest Oncol* 2019; In press

**INTRODUCTION**

Colorectal cancer (CRC) is the third most common cancer in the United States of America, while it is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths worldwide by 2030[1,2]. In 2014, almost 153,000 patients died from CRC in the European Union, where it is the second leading cause of cancer death (Eurostat. Cancer statistics – specific cancers)[3]. At diagnosis, 74%-76% of patients have localized or regional CRC. Fluoropyrimidines remain the backbone of adjuvant chemotherapy for early stage CRC patients after curative surgery[4,5]. Fluoropyrimidines exert their effect in different ways, but mainly by inhibiting the *de novo* formation of thymidylate (dTMP) from uridylate (dUMP)[6]. Other mechanisms of action are more complex than simple inhibition of thymidine synthase (TS) expression, as they involve inhibition of DNA synthesis and function through misincorporation of FdUTP into cellular DNA and inhibition of RNA processing and mRNA translation through the incorporation of FUTP into cellular RNA[7]. The use of fluoropyrimidines is associated with reduction of recurrence in only 25% of patients with stage III CRC[8,9]. Only 3%-7% of patients with stage II CRC will benefit from adjuvant chemotherapy[10]. The variability of observed survival outcomes has been largely attributed to molecular heterogeneity, and *KRAS*, *BRAF* and thymidylate synthase (*TYMS)* are being investigated to this end[11]. *KRAS* belongs to the RAS subfamily of genes that encodes a 21-kDa small-GTPase[12]. Activating mutations in RAS result in activation of major signaling pathways downstream of epidermal growth factor receptor (commonly known as EGFR), stimulating cell proliferation and inhibiting apoptosis[13]. In the metastatic disease setting, *KRAS* mutation (m*KRAS*) is a predictor of resistance to EGFR inhibitors and is directly linked to poor patient survival, while its role in the adjuvant setting is under investigation[14-16].

*BRAF* is an essential part of the RAS/RAF/MAP2K (MEK)-MAPK signaling cascade, and its mutations have been likewise associated with inferior survival in CRC patients after curative resection and adjuvant chemotherapy[17,18].

The *TYMS* gene (GeneID 7298) is located on the short arm of chromosome 18 (18p11.32). There is conflicting evidence on the role of *TYMS* polymorphisms in predicting response to 5-fluorouracil (5FU)–based chemotherapy[19-25]. The loss of heterozygosity (LOH) at the *TYMS* locus on chromosome 18 has been implicated as a factor affecting the related resistance to fluoropyrimidine-based therapy[26].

A *TYMS* polymorphism of the 5’ untranslated region (5’ UTR) is caused by the insertion of a 28 base-pair (bp) sequence (rs34743033)[19]. From the resulting alleles that may include two or three 28 bp tandem repeats (2R or 3R respectively), the 3R allele has been associated with increased TYMS protein expression and TYMS enzyme activity[27,28]. A G->C single nucleotide polymorphism (SNP) in the tandem repeat sequence [rs2853542] was found to reduce the translational efficiency of 3R to 2R[19,29]. Based on the presence of SNP polymorphisms (G or C), 3R is characterized as 3RG or 3RC. In addition, the 3’ UTR may contain a 6-bp polymorphism (rs34489327) that affects *TYMS* mRNA stability, resulting in increased intratumoral *TYMS* mRNA[19,30]. Depending on the presence of this 6-bp polymorphism, the three resulting genotypes are ins/ins (homozygous for insertion of 6 bp), del/del (homozygous for deletion) and ins/del (heterozygous).

Taken together, the identification of potential markers that could identify the patient subgroups that could benefit most from fluoropyrimidine-based therapy remains an unmet clinical need.

The present study aims to investigate the associations of *TYMS* polymorphisms, LOH, m*KRAS* and *BRAF* mutations (m*BRAF*) with clinicopathologic characteristics and survival outcomes of CRC patients treated with fluoropyrimidine-based adjuvant chemotherapy.

**MATERIALS AND METHODS**

***Patients and clinical data***

This was a retrospective study carried out by a single institution (University General Hospital “ATTIKON”). Formalin-fixed paraffin-embedded tissues (FFPE) and clinical data of consecutive patients with CRC referred for adjuvant chemotherapy from January 2005 to January 2007 were retrieved. Of these, only patients with histologies reporting R0 surgical margins and treated with fluoropyrimidine-based adjuvant chemotherapy (and therefore with no residual disease) were included in the analysis. In these cases, the integrity of the mesocolon/mesorectum was preserved.

***DNA extraction protocol***

DNA was extracted from 5-μm thick FFPE sections containing at least 30% malignant cells, using a commercially available kit (Purelink Genomic DNA kit, Thermo Fisher Scientific, Germany). DNA was quantified by qPCR (Quant-iT™ PicoGreen® dsDNA Assay Kit, Thermo Fisher Scientific, Germany) and was diluted to a concentration of 10 ng/μL for *TYMS* polymorphisms and 4 ng/μL for m*KRAS* detection.

***TYMS polymorphisms***

Analysis was carried-out as previously described[31,32]. PCR was performed using 1 U Platinum® *Taq* DNA Polymerase (Thermo Fisher Scientific, Germany), 1.5 mmol/L Mg and 200 nmol/L dNTPs and primers. Although the same primers were used, 5’-UTR amplification was performed using a GC rich amplification kit (PCRx Enhancer System, Thermo Fisher Scientific, Germany) adding 1× of PCRx Enhancer. Genotyping for the 2R/3R polymorphism was performed by running 10 μL of PCR product on a 1.5% agarose gel and staining with Ethidium Bromide as previously described (Ntavatzikos *et al*[31]). Similarly, for the 12G>C substitution, 10 μL PCR product was digested with 1 U HaeIII restriction enzyme (Takara, Japan) at 37˚C for 1 h and run on an 8% 19:1 polyacrylamide gel. Polyacrylamide gels were used for 3’ UTR analysis. LOH analysis was achieved by analyzing the intensity of the 5’ UTR and 3’ UTR bands in pictures acquired using the GeneTools software (Syngene, United Kingdom). The sample was categorized as having LOH if one of the bands had an intensity score < 50% of the other. Samples showing LOH were defined as 2R/3RGLOH, 2RLOH/3RG, 2R/3RCLOH and 2RLOH/3RC, indicating the allele that was partially lost. For quality control, selected products were sequenced to verify the sequence amplified. The amplified product was 242 bp for 3R and 214 bp for 2R polymorphisms, as revealed by the BLAST results of the sequenced products and the alignment with the latest human assemblies.

***Mutational analysis***

Detection of m*KRAS* in codons 12 and 13 and *BRAF* activating mutation V600E were performed as previously described with a commercially available Real-Time PCR kit (Therascreen KRAS, DxS Diagnostics, United Kingdom), which can detect six mutations in codon 12 (G12D, G12A, G12V, G12S, G12R, G12C) and one mutation in codon 13 (G13D)[31,33]. A positive reaction mix for all mutations was included. To avoid false negative results caused by PCR inhibitors, a second exogenous reaction was simultaneously performed. If the sample’s ΔCt (Ct of control reaction-Ct mutation reaction) was lower than the value set by the manufacturer, then it was characterized as bearing a mutation. BRAF activating mutation V600E was identified using molecular beacons as previously described[33]. One beacon for the wild type and one for the mutant allele were added at a final concentration of 100 nmol/L in a 25 μL PCR reaction containing 1× PCR Buffer, 6 mmol/L MgCl2, 200 nmol/L dNTPs, 300 nmol/L of each primer and 1 U Platinum® Taq. The PCR protocol was 95˚C for 2 min, followed by 40 cycles of 95˚C for 10 sec, 62˚C for 60 sec and 72˚C for 20 sec. DNA extracts from SKMEL2 and SKMEL20 melanoma cell lines were used as positive controls for both the wild type and mutant allele (CLS, Germany). The ABI 7500 Fast (Thermo Fisher Scientific, Germany) was used to perform all Real-Time PCR experiments.

***TYMS-gene polymorphisms stratification model***

Based on the predicted *TYMS* protein expression, 5’ UTR polymorphisms were assigned into low (2RG/2RG, 2RG/3RC, 3RC/3RC), medium (2RG/3RG, 2RG/3RCLOH, 2RG/3RGLOH, 2RGLOH/3RC) and high TYMS protein expression groups (3RG/3RG, 3RG/3RC, 2RGLOH/3RG)[31]. The effect of each 3’ UTR polymorphism was examined against the others by applying univariate analysis, and it was found that only the ins/LOH polymorphism had a statistically significant effect. Based on this finding, 3’ UTR polymorphisms were allocated into two groups depending on the presence of ins/LOH**.** This classification is depicted in Table 1.

***Statistical analysis***

Association of *TYMS* polymorphisms with selected clinicopathological characteristics was performed using the *χ*2 test with a two-sided significance of 0.05. Time-to-event distributions were estimated using the Kaplan-Meier method. For all associations, the level of statistical significance was set at a = 0.05. Overall survival (OS) was defined as the interval between the initiation of adjuvant chemotherapy and death of any cause. Disease-free survival (DFS) was defined as the time from adjuvant chemotherapy initiation to the first recurrence or death by any cause.

Surviving patients were censored at the date of last contact.Cox proportional hazards model was used to estimate the relationship of clinicopathological parameters and *TYMS* polymorphisms with OS and DFS. The relationship of *TYMS* polymorphisms groups with OS and DFS was assessed by univariate Cox regression analysis. The final multivariate model was selected using a backward selection procedure, starting from an initial model that included all potential risk factors and *TYMS* polymorphisms. Model selection was based on a likelihood ratio test, while the removal criterion was set at 0.10. All statistical analyses were performed using the SPSS software version 24.0 (SPSS Inc, Chicago, IL, United States). The statistical methods of this study were reviewed by Georgia Vourli from the Department of Hygiene, Epidemiology and Medical Statistics, Medical School University of Athens.

**RESULTS**

***Patient characteristics***

Medical records of 130 consecutive patients and their FFPE were retrieved for analysis. Patients’ clinicopathologic data including age, gender, primary tumor site, histological grade, treatment and survival are shown in Table 2. With a median follow-up of 71.2 mo (range 0.5-157), 51 patients (39.2%) experienced disease recurrence and 45 patients (34.6%) died. The 5-year OS and DFS rate was 73.9% and 61.6%, respectively.

The frequency of *TYMS* polymorphisms involving G>C SNP and LOH are presented in Table 3. Significant associations were found among patients’ tumor characteristics and polymorphisms, as shown in Table 4.

***Univariate survival analysis***

Univariate Cox regression analysis of *TYMS* polymorphisms, m*KRAS* and m*BRAF*, LOH and selected clinicopathological patients’ characteristics are shown in Table 5. Univariate analysis indicated a trend for a better DFS and OS in the group of 5’ UTR polymorphisms with medium expression profile (group B), while ins/LOH polymorphism of the 3’ UTR was associated with worse DFS and OS. The analysis of m*KRAS* showed no significant effect on survival whereas the *BRAF* V600E mutation was associated with increased risk of death. Clinical variables close to statistical significance were age (< 65 years old *vs* ≥ 65 years old), primary site (rectal *vs* colon), histological grade (III-IV *vs* I-II) and stage (III *vs* Ι and II).

***Multivariate survival analysis***

Results of the multivariate analysis including *TYMS* polymorphisms, m*BRAF* and selected clinicopathological characteristics are shown in Table 6. From the 5’ UTR polymorphisms, group A (2RG/2RG, 2RG/3RC, 3RC/3RC) and group C (3RG/3RG, 3RG/LOH, 3RG/3RC) were associated with higher risk for disease recurrence and death compared to group B (2RG/3RG, 2RG/LOH and 3RC/LOH). Similarly, group B of the 3’ UTR polymorphism (ins/LOH) was associated with increased risk of relapse and death compared to group A.

Kaplan-Meier curves for DFS and OS according to *TYMS* 3’ UTR and 5’ UTR polymorphisms groups are shown in Figure 1. Stage III independently increased the risk of relapse, while the *BRAF* mutation independently increased the risk of death. Kaplan-Meier curves for OS according to m*BRAF* are shown in Figure 2.

**DISCUSSION**

This is a retrospective study of 130 CRC patients treated with surgery and adjuvant chemotherapy, studying for the first time the correlation of *TYMS* polymorphisms, LOH, m*KRAS* and m*BRAF* with survival outcomes. We report that polymorphisms in the 3’ UTR and 5’ UTR of *TYMS* were independent factors associated with risk of disease relapse and death. In particular, ins/LOH increased the risk of disease relapse and death, while the group of 5’ UTR polymorphisms containing 2RG/3RG, 2RG/LOH and 3RC/LOH decreased the risk of disease relapse and death. The study of m*KRAS* pointed out that it was not associated with disease relapse or related death, while the m*BRAF* independently increased the risk of death.

Since the early studies of adjuvant chemotherapy treatment with 5FU 23 years ago, there have been two landmark advances in the field[34]. The first involved the incorporation of oral capecitabine as an alternative to intravenously administered 5FU[35]. The second was the addition of oxaliplatin to 5FU, which led to a 4.2% absolute improvement in OS of patients with T4 and N1 disease (stage III disease; MOSAIC trial) whereas stage II patients did not benefit[36,37]. As clinicopathologic parameters are important but not sufficiently useful in deciding which patients with stage II-III will benefit from adjuvant chemotherapy, molecular markers are essential[38]. Several studies have reported the association of *TYMS* polymorphisms, *TYMS* mRNA and *TYMS* protein expression with survival in CRC patients, but with inconsistent findings[20-22,24,39-43]. A meta-analysis indicated that patients with advanced CRC tumors expressing high levels of TYMS had a poorer OS compared to tumors expressing low levels[44]. On the contrary, a subsequent prospective blinded analysis of TYMS expression in the adjuvant treatment of CRC concluded that TYMS expression did not show a significant prognostic value[45]. None of the studies included *mBRAF* status or different *TYMS* polymorphism in their multivariate analysis.

***5’ UTR polymorphisms***

In this study, *TYMS* polymorphisms emerged as prognostic factors for survival outcomes in patients treated with surgery and adjuvant chemotherapy. More specifically, group B (2RG/3RG, 2RG/3RCLOH, 2RG/3RGLOH, 2RGLOH/3RC) was shown to have the lowest risk of recurrence and a trend for lower risk of death compared to the other two groups A (2RG/2RG, 2RG/3RC, 3RC/3RC) and C (3RG/3RG, 3RG/3RC, 2RGLOH/3RG). Similarly, a previous study showed that 5’ UTR polymorphisms were associated with survival. In particular, they reported that ‘low risk’ polymorphisms (2RG/2RG, 2RG/3RC, 3RC/3RC) were associated with improved DFS regardless of chemotherapy treatment[40]. On the contrary, a previous study indicated that *TYMS* 5’ UTR polymorphisms do not predict clinical outcome of CRC patients treated with 5-FU based chemotherapy[39]. Nevertheless, neither of these two studies took into consideration a combined analysis of 3’ UTR polymorphisms, LOH or m*BRAF* status. In addition, the categorization of the *TYMS* 5’ UTR polymorphisms into only two groups (high expression group: 2RG/3RG, 3RC/3RG, 3RG/3RG and low expression group: 2RG/2RG, 2RG/3RC, 3RC/3RC) entails the risk of classification error. Indeed, in this way, both studies placed the 2RG/3RG with the high expression 3RG/3RG, although 2RG/3RG is a member of the heterozygous 5’ UTR polymorphisms group that are generally considered to have an intermediate expression profile[27,46]. Our study identified heterozygotes, such as 2RG/3RG, 2RG/LOH and 3RC/LOH, as independent good prognostic factors for recurrence and death in CRC patients treated with surgery and adjuvant chemotherapy.

***3’ UTR polymorphisms***

In our study, 3’ UTR polymorphism ins/LOH was found to independently increase the risk for both relapse and death. Comparably, two other studies outlined the negative effect of the ins allele in the therapeutic outcome of CRC patients treated with adjuvant chemotherapy and neoadjuvant setting in rectal cancer patients[41,47]. On the contrary, another study found that ins/ins with 2R/3R and any 3’ UTR polymorphism with 3R/3R predict longer DFS and OS in CRC patients treated with adjuvant 5FU-based chemotherapy[22]. However, in the later study, the G>C SNP and LOH status were not taken into consideration.

***KRAS and BRAF***

The present study showed that the rate of m*BRAF* identified in our population (3.8%) was lower than expected, as previously reported rates in the adjuvant setting ranged from 7.9% to 17%[17,36,48]. Although m*BRAF* was not associated with the risk of relapse, m*BRAF* independently increased the risk of death. In agreement with our study, three previous studies linked m*BRAF* to poor survival in relation with MSI status[17,48,49]. A fourth study reported that m*BRAF* was an adverse prognostic factor for both DFS and OS, independently of MSI status[50]. Contrary to these studies, another study indicated that BRAF mutations did not confer a worse prognosis[36]. In contrast to our study, none of the above studies took into consideration *TYMS* polymorphisms.

In this study, mutated *KRAS* did not emerge as a predictive factor for survival in the univariate analysis. Similar to ours, two previous studies indicated that m*KRAS* was not associated with survival in stage II/III CRC patients[48,51]. On the contrary, a more recent study reported that the risk of recurrence was higher for m*KRAS* compared to wild type *KRAS* tumors[52]. More recently, another study reported that m*KRAS* had prognostic impact on DFS and OS independently of microsatellite instability status[50]. None of the above studies took into consideration *TYMS* polymorphisms.

***Other findings of the analysis***

We found that patients born from 1943 onwards more frequently had the 3RG/3RG polymorphism and high-grade malignancy tumors (RR 1.730, 95% CI: 1.088-2.747; *P* = 0.030). Two previous studies have also linked age to *TYMS* polymorphisms and protein expression in CRC[53,54]. As more data gather, the differences in the frequency of polymorphisms among generations are of great interest. These differences could derive from epigenetic modifications induced by environmental changes during the course of human life[55]. Another important open question is whether in younger generations, *TYMS* polymorphisms are associated with higher risk of developing aggressive cancer due to changes in the genetic substrate.

We report for the first time that m*KRAS* had a strong correlation with the 3RG/3RC polymorphism and with polymorphisms that contain only the 3RC allele (3RC/3RC, 3RC/LOH). Contrary to our findings, a previous study reported no significant relationship between any of the *TYMS* polymorphisms with tumor characteristics[56]. However, in the understudy grouping of *TYMS* polymorphisms, LOH was not considered.

***Limitations***

Although the size of this study’s patient cohort is one of the largest reported, it is still difficult to analyze the large sum of polymorphisms resulting from the combination of 3’ UTR and 5’ UTR polymorphisms, G>C SNP and LOH. Another limitation is that subsequent chemotherapy lines following disease relapse were not included in the survival analysis. An important limitation is that classification of *TYMS* polymorphisms into groups was based on our statistical analysis and previously published data but requires further validation in prospective trials.

Another important limitation is that the levels of *TYMS* protein expression and activity were not examined. Although immunohistochemical analysis of *TYMS* protein expression is considered important, several studies have shown that *TYMS* protein expression is affected by several factors, like p53 mutation and other genes that have been shown to affect the final level of *TYMS* expression, including astrocyte elevated gene-1 (*AEG-1*) and enolase superfamily member 1 (*ENOSF1*) during the course of the disease[57-60]. It has been reported that there is discordance in *TYMS* mRNA expression and TYMS protein levels between primary tumors and their metastasis[61-63]. Furthermore, the binding of TYMS protein to its own mRNA, as well as the binding of TYMS to *p53* mRNAcauses translational repression in an autoregulatory translational manner[64-66]. Other significant prognostic and predictive markers such as NRAS, PIK3CA exon 20 and MMR/MSI were not included in this analysis[64-66].

In conclusion, the group of *TYMS* polymorphisms 2RG/3RG, 2RG/LOH and 3RC/LOH and the absence of ins/LOH was associated with better prognosis in CRC patients treated with adjuvant chemotherapy, while m*BRAF* was associated with increased risk of death. Proof of concept, prospective studies are required to validate our findings.

**ARTICLE HIGHLIGHTS**

***Research background***

A large proportion of patients with colorectal cancer (CRC) do not benefit from fluoropyrimidine-based adjuvant chemotherapy. Fluoropyrimidines are thymidylate synthase (TYMS) inhibitors. Single nucleotide polymorphism (SNP) and various polymorphisms have been discovered in the 5’ untranslated region (UTR) and in the 3’ UTR of the *TYMS* gene, and their association with the survival of CRC patients is under consideration but with conflicting results. Molecular profiling could help clinicians identify CRC patients who may benefit from adjuvant chemotherapy, as shown by the associations of BRAF mutations with inferior survival in CRC patients after adjuvant chemotherapy. Also, although *KRAS* mutations have been found to be associated with poor patient survival, their role in the adjuvant setting is under investigation.

***Research motivation***

There is a need to study the association of the numerous combinations of TYMS polymorphisms (3’ UTR, 5’ UTR and SNP) with CRC patient survival in a multivariate model including clinicopathological patients’ features and *KRAS/BRAF* mutations. Loss of heterozygosity (LOH) affects polymorphisms and should be included in such a study.

***Research objectives***

This study aimed to investigate the association of all known *TYMS* gene polymorphisms, LOH*, KRAS* and *BRAF* mutations with the survival of CRC patients treated with adjuvant chemotherapy.

***Research methods***

Formalin-fixed paraffin-embedded tissues of 130 consecutive patients treated with fluoropyrimidine-based adjuvant chemotherapy were analyzed for the detection of *TYMS* polymorphisms, *mKRAS* and *mBRAF*. Patients were classified into three groups according to 5’ UTR *TYMS* polymorphisms and the predicted expression profile (high, medium and low expression), utilizing the current literature. This categorization could reduce classification errors. Based on the presence or absence of the 3’ UTR polymorphism ins/LOH, patients were allocated into two groups (high and low risk of relapse), utilizing the results from univariate analysis of the 3’ UTR *TYMS* polymorphisms. Cox regression models examined the associated 5-year survival outcomes.

***Research results***

In this study, where *BRAF*, *TYMS* polymorphisms including SNP G>C and LOH were taken into consideration, both 3’ UTR and 5’ UTR polymorphisms emerged as independent prognostic factors of survival outcome after adjuvant chemotherapy for CRC. More specifically, the group of patients with tumors bearing 5’ UTR polymorphisms 2RG/3RG, 2RG/LOH and 3RC/LOH was associated with better survival. On the contrary, patients with ins/LOH polymorphism in the 3’ UTR had worse survival outcome. Also, *mBRAF* was found to independently correlate with worse prognosis.

***Research conclusions***

Knowledge o*f TYMS* gene polymorphisms and *BRAF* status indicates prognosis and could aid clinicians to distinguish the group of patients in need of adjuvant chemotherapy.

***Research perspectives***

The study of the effect on the survival of CRC patients of the numerous genotypes resulting from the combinations of the 3’ UTR and 5’ UTR polymorphisms, the SNP and LOH requires larger prospective studies. These studies could validate our findings. Also, they could facilitate the grouping of *TYMS* polymorphisms in more than just two groups and thus reduce the classification errors.

**ACKNOWLEDGEMENTS**

We dedicate this manuscript to the late Petros Karakitsos, our mentor and colleague who founded the lab of cellular and molecular biology where this work was carried out. He will always be remembered with love.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

2 **Arnold M**, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017; **66**: 683-691 [PMID: 26818619 DOI: 10.1136/gutjnl-2015-310912]

3 **Eurostat**. Cancer statistics - specific cancers. 2017. Available from: URL: http://ec.europa.eu/eurostat/statistics-explained/index.php/Cancer\_statistics\_-\_specific\_cancers

4 **Siegel RL**, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017; **67**: 177-193 [PMID: 28248415 DOI: 10.3322/caac.21395]

5 **Cunningham D**, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. *Lancet* 2010; **375**: 1030-1047 [PMID: 20304247 DOI: 10.1016/S0140-6736(10)60353-4]

6 **Bijnsdorp IV**, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. *Oncol Rep* 2007; **18**: 287-291 [PMID: 17549381 DOI: 10.3892/or.18.1.287]

7 **Humeniuk R**, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. *Mol Cancer Ther* 2009; **8**: 1037-1044 [PMID: 19383847 DOI: 10.1158/1535-7163.MCT-08-0716]

8 **Longley DB**, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 2003; **3**: 330-338 [PMID: 12724731 DOI: 10.1038/nrc1074]

9 **de Gramont A**, Larsen AK, Tournigand C, Louvet C, André T; GERCOR (French Oncology Research Group). Update on targeted agents for adjuvant treatment of colon cancer in 2006. *Gastrointest Cancer Res* 2007; **1**: S47-S49 [PMID: 19360148]

10 **Quasar Collaborative Group**, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet* 2007; **370**: 2020-2029 [PMID: 18083404 DOI: 10.1016/S0140-6736(07)61866-2]

11 **Sinicrope FA**, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. *Clin Gastroenterol Hepatol* 2016; **14**: 651-658 [PMID: 26872400 DOI: 10.1016/j.cgh.2016.02.008]

12 **Karnoub AE**, Weinberg RA. Ras oncogenes: split personalities. *Nat Rev Mol Cell Biol* 2008; **9**: 517-531 [PMID: 18568040 DOI: 10.1038/nrm2438]

13 **Adjei AA**. Blocking oncogenic Ras signaling for cancer therapy. *J Natl Cancer Inst* 2001; **93**: 1062-1074 [PMID: 11459867 DOI: 10.1093/jnci/93.14.1062]

14 **De Roock W**, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; **11**: 753-762 [PMID: 20619739 DOI: 10.1016/S1470-2045(10)70130-3]

15 **Deng Y**, Wang L, Tan S, Kim GP, Dou R, Chen D, Cai Y, Fu X, Wang L, Zhu J, Wang J. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. *Mol Oncol* 2015; **9**: 1341-1347 [PMID: 25864038 DOI: 10.1016/j.molonc.2015.03.006]

16 **Taieb J**, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. *JAMA Oncol* 2016; **2**: 643-653 [PMID: 26768652 DOI: 10.1001/jamaoncol.2015.5225]

17 **Ogino S**, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. *Clin Cancer Res* 2012; **18**: 890-900 [PMID: 22147942 DOI: 10.1158/1078-0432.CCR-11-2246]

18 **Zhu L**, Dong C, Cao Y, Fang X, Zhong C, Li D, Yuan Y. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials. *PLoS One* 2016; **11**: e0154795 [PMID: 27138801 DOI: 10.1371/journal.pone.0154795]

19 **National Library of Medicine**. USNLoM. In: Information NCfB, editor, 2017. Available from: URL: https://www.nlm.nih.gov/

20 **Ciaparrone M**, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. *Oncology* 2006; **70**: 366-377 [PMID: 17179731 DOI: 10.1159/000098110]

21 **Edler D**, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. *J Clin Oncol* 2002; **20**: 1721-1728 [PMID: 11919227 DOI: 10.1200/JCO.2002.07.039]

22 **Hitre E**, Budai B, Adleff V, Czeglédi F, Horváth Z, Gyergyay F, Lövey J, Kovács T, Orosz Z, Láng I, Kásler M, Kralovánszky J. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. *Pharmacogenet Genomics* 2005; **15**: 723-730 [PMID: 16141798 DOI: 10.1097/01.fpc.0000175598.42141.59]

23 **Kostopoulos I**, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. *BMC Cancer* 2009; **9**: 339 [PMID: 19775480 DOI: 10.1186/1471-2407-9-339]

24 **Koumarianou A**, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. *Anticancer Res* 2014; **34**: 4949-4962 [PMID: 25202077 DOI: 10.1245/s10434-014-3557-1]

25 **Tsuji T**, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M, Shibasaki S, Nanashima A, Yamaguchi H, Yasutake T, Tagawa Y. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. *Clin Cancer Res* 2003; **9**: 3700-3704 [PMID: 14506161 DOI: 10.1093/carcin/bgg126]

26 **Uchida K**, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD, Danenberg PV. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. *Clin Cancer Res* 2004; **10**: 433-439 [PMID: 14760062 DOI: 10.1158/1078-0432.CCR-0200-03]

27 **Kawakami K**, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. *Clin Cancer Res* 2001; **7**: 4096-4101 [PMID: 11751507 DOI: 10.1159/000048556]

28 **Marsh S**. Thymidylate synthase pharmacogenetics. *Invest New Drugs* 2005; **23**: 533-537 [PMID: 16267625 DOI: 10.1007/s10637-005-4021-7]

29 **Mandola MV**, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. *Cancer Res* 2003; **63**: 2898-2904 [PMID: 12782596 DOI: 10.1016/j.tate.2006.04.018]

30 **Mandola MV**, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. *Pharmacogenetics* 2004; **14**: 319-327 [PMID: 15115918 DOI: 10.1097/00008571-200405000-00007]

31 **Ntavatzikos A**, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumarianou A. Integrating <i>TYMS</i>, <i>KRAS</i> and <i>BRAF</i> testing in patients with metastatic colorectal cancer. *World J Gastroenterol* 2017; **23**: 5913-5924 [PMID: 28932083 DOI: 10.3748/wjg.v23.i32.5913]

32 **Lecomte T**, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. *Clin Cancer Res* 2004; **10**: 5880-5888 [PMID: 15355920 DOI: 10.1158/1078-0432.CCR-04-0169]

33 **Spathis A**, Georgoulakis J, Foukas P, Kefala M, Leventakos K, Machairas A, Panayiotides I, Karakitsos P. KRAS and BRAF mutation analysis from liquid-based cytology brushings of colorectal carcinoma in comparison with formalin-fixed, paraffin-embedded tissue. *Anticancer Res* 2010; **30**: 1969-1975 [PMID: 20651341 DOI: 10.1097/CAD.0b013e328338b6a5]

34 **Moertel CG**, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. *Ann Intern Med* 1995; **122**: 321-326 [PMID: 7847642 DOI: 10.7326/0003-4819-122-5-199503010-00001]

35 **Twelves C**, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005; **352**: 2696-2704 [PMID: 15987918 DOI: 10.1056/NEJMoa043116]

36 **André T**, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 2009; **27**: 3109-3116 [PMID: 19451431 DOI: 10.1200/JCO.2008.20.6771]

37 **Sanoff HK**, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. *J Clin Oncol* 2012; **30**: 2624-2634 [PMID: 22665536 DOI: 10.1200/JCO.2011.41.1140]

38 **Auclin E**, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. *Ann Oncol* 2017; **28**: 958-968 [PMID: 28453690 DOI: 10.1093/annonc/mdx030]

39 **Park CM**, Lee WY, Chun HK, Cho YB, Yun HR, Heo JS, Yun SH, Kim HC. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. *J Surg Oncol* 2010; **101**: 22-27 [PMID: 19798689 DOI: 10.1002/jso.21412]

40 **Sulzyc-Bielicka V**, Bielicki D, Binczak-Kuleta A, Kaczmarczyk M, Pioch W, Machoy-Mokrzynska A, Ciechanowicz A, Gołębiewska M, Drozdzik M. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. *Genet Test Mol Biomarkers* 2013; **17**: 799-806 [PMID: 23968134 DOI: 10.1089/gtmb.2013.0171]

41 **Dotor E**, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G, Villanueva A. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. *J Clin Oncol* 2006; **24**: 1603-1611 [PMID: 16575011 DOI: 10.1200/JCO.2005.03.5253]

42 **Matsui T**, Omura K, Kawakami K, Morita S, Sakamoto J. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. *Oncol Rep* 2006; **16**: 1111-1115 [PMID: 17016601 DOI: 10.3892/or.16.5.1111]

43 **Wang J**, Shi D, Guo X, Zhang J, Yu S, Song J, Cao Z, Wang J, Ji M, Dong W. Thymidylate synthase genetic polymorphisms and colorectal cancer risk: a meta-analysis. *Clin Res Hepatol Gastroenterol* 2014; **38**: 481-490 [PMID: 24685603 DOI: 10.1016/j.clinre.2014.02.006]

44 **Popat S**, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. *J Clin Oncol* 2004; **22**: 529-536 [PMID: 14752076 DOI: 10.1200/JCO.2004.05.064]

45 **Popat S**, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, Shao Y, Aherne W, Houlston R. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. *Ann Oncol* 2006; **17**: 1810-1817 [PMID: 16971666 DOI: 10.1093/annonc/mdl301]

46 **Horie N**, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. *Cell Struct Funct* 1995; **20**: 191-197 [PMID: 7586009 DOI: 10.1247/csf.20.191]

47 **Stoehlmacher J**, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, Liersch T, Ehninger G, Jakob C. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. *Cancer Lett* 2008; **272**: 221-225 [PMID: 18722050 DOI: 10.1016/j.canlet.2008.07.008]

48 **Roth AD**, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010; **28**: 466-474 [PMID: 20008640 DOI: 10.1200/JCO.2009.23.3452]

49 **Seppälä TT**, Böhm JP, Friman M, Lahtinen L, Väyrynen VM, Liipo TK, Ristimäki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. *Br J Cancer* 2015; **112**: 1966-1975 [PMID: 25973534 DOI: 10.1038/bjc.2015.160]

50 **Kadowaki S**, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. *World J Gastroenterol* 2015; **21**: 1275-1283 [PMID: 25632202 DOI: 10.3748/wjg.v21.i4.1275]

51 **Ogino S**, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Canadian Cancer Society Research Institute; Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. *Clin Cancer Res* 2009; **15**: 7322-7329 [PMID: 19934290 DOI: 10.1158/1078-0432.CCR-09-1570]

52 **Hutchins G**, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol* 2011; **29**: 1261-1270 [PMID: 21383284 DOI: 10.1200/JCO.2010.30.1366]

53 **Odin E**, Wettergren Y, Nilsson S, Carlsson G, Gustavsson B. Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels. *Clin Colorectal Cancer* 2007; **6**: 720-727 [PMID: 18039426 DOI: 10.3816/CCC.2007.n.042]

54 **Fariña-Sarasqueta A**, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. *Cell Oncol (Dordr)* 2011; **34**: 327-335 [PMID: 21630057 DOI: 10.1007/s13402-011-0030-z]

55 **Marsh S**, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. *Genomics* 1999; **58**: 310-312 [PMID: 10373329 DOI: 10.1006/geno.1999.5833]

56 **Etienne-Grimaldi MC**, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, Formento JL, Formento P, Sudaka A, Boige V, Abderrahim-Ferkoune A, Benchimol D, André T, Houry S, Faucheron JL, Letoublon C, Gilly FN, Delpero JR, Lasser P, Pradere B, Pezet D, Penault-Llorca F, Milano G. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. *Br J Cancer* 2014; **110**: 2728-2737 [PMID: 24800948 DOI: 10.1038/bjc.2014.213]

57 **Nief N**, Le Morvan V, Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. *Eur J Cancer* 2007; **43**: 955-962 [PMID: 17317154 DOI: 10.1016/j.ejca.2006.12.012]

58 **Yoo BK**, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D. Identification of genes conferring resistance to 5-fluorouracil. *Proc Natl Acad Sci U S A* 2009; **106**: 12938-12943 [PMID: 19622726 DOI: 10.1073/pnas.0901451106]

59 **Rosmarin D**, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. *J Clin Oncol* 2014; **32**: 1031-1039 [PMID: 24590654 DOI: 10.1200/JCO.2013.51.1857]

60 **Vignoli M**, Nobili S, Napoli C, Putignano AL, Morganti M, Papi L, Valanzano R, Cianchi F, Tonelli F, Mazzei T, Mini E, Genuardi M. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. *Pharmacol Res* 2011; **64**: 242-248 [PMID: 21536130 DOI: 10.1016/j.phrs.2011.04.006]

61 **Aschele C**, Debernardis D, Tunesi G, Maley F, Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. *Clin Cancer Res* 2000; **6**: 4797-4802 [PMID: 11156237 DOI: 10.1093/carcin/21.12.2293]

62 **Kumamoto K**, Kuwabara K, Tajima Y, Amano K, Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N, Ishida H. Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. *Oncol Lett* 2012; **3**: 983-989 [PMID: 22783377 DOI: 10.3892/ol.2012.598]

63 **Marsh S**, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. *Oncol Rep* 2002; **9**: 231-234 [PMID: 11836585 DOI: 10.3892/or.9.2.231]

64 **Chu E**, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. *Proc Natl Acad Sci U S A* 1991; **88**: 8977-8981 [PMID: 1924359 DOI: 10.1073/pnas.88.20.8977]

65 **Chu E**, Voeller DM, Jones KL, Takechi T, Maley GF, Maley F, Segal S, Allegra CJ. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. *Mol Cell Biol* 1994; **14**: 207-213 [PMID: 8264588 DOI: 10.1128/MCB.14.1.207]

66 **Liu Q**, Yu Z, Xiang Y, Wu N, Wu L, Xu B, Wang L, Yang P, Li Y, Bai L. Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis. *Cancer Biomark* 2015; **15**: 65-78 [PMID: 25524944 DOI: 10.3233/CBM-140432]

**P-Reviewer:** Arslan NC, Kasi PM, Watanapokasin R **S-Editor:** Ji FF

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Oncology

**Country of origin:** Greece

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**5’UTR polymorphisms**

**Group A**

**Group Ba**


**Group C**

**censored**

**Disease free survival time (mo)**

**Cumulative disease free survival**

**A**



**Cumulative overall survival**

**Survival time (mo)**

**5’UTR polymorphisms**


**Group A**

**Group Ba**

**Group C**

**censored**

**B**



**Cumulative disease free survival**

**Disease free survival time (mo)**


**3’UTR polymorphisms**

**ins/LOH**

**Other polymorphismsb**

**censored**

**C**



**Cumulative overall survival**

**Survival time (mo)**

**3’UTR polymorphisms**


**ins/LOH**

**Other polymorphismsb**

**censored**

**D**

**Figure 1 Kaplan-Meier curves for disease free survival and overall survival according to thymidylate synthase polymorphisms.** A: Disease free survival (DFS) according to the 5’ untranslated region (UTR); B: Overall survival (OS) according to 5’ UTR; C: DFS according to 3’; UTR; D: OS according to 3’ UTR. a*P* < 0.05 *vs* Group A and C; b*P* < 0.005. LOH: Loss of heterozygosity.



**Cumulative overall survival**

**Survival time (mo)**

**BRAF**

**V600E**

**WTa**

**censored**

**Figure 2 Kaplan-Meier survival curve for overall survival according to *BRAF* mutation status (V600E *vs* WT - wild type).** a*P* < 0.05.

**Table 1 *TYMS* polymorphism groups according to risk group and level of expression**

|  |  |
| --- | --- |
| **Groups** | **Polymorphisms** |
| 3’ UTR |  |
| A (low risk) | del/del |
|  | del/LOH |
|  | ins/del |
|  | ins/ins |
| B (high risk) | ins/LOH |
| 5’ UTR |  |
| A (low expression) | 2RG |
|  | 2RG/3RC |
|  | 3RC |
| B (medium expression) | 2RG/3RG |
|  | 2RG/3RCLOH |
|  | 2RG/3RGLOH |
|  | 2RGLOH/3RC |
| C (high expression) | 3RG |
|  | 3RG/3RC |
|  | 2RGLOH/3RG |

UTR: Untranslated region; LOH: Loss of heterozygosity.

**Table 2 Clinicopathologic data for colorectal cancer patients treated with adjuvant chemotherapy**

|  |  |
| --- | --- |
| **Clinicopathologic data** | **Total, *n* = 130** |
| Median age (range) | 67 (37-88) |
| Male | 79 (60.8) |
| Primary site |  |
| Rectum | 60 (46.2) |
| Positive lymph nodes | 76 (58.5) |
| Stage according to AJCC |  |
| I | 1 (0.8) |
| II | 54 (41.5) |
| III | 75 (57.7) |
| Histological grade |  |
| I + II | 83 (63.8) |
| III + IV | 47 (36.2) |
| *KRAS* mutation | 48 (36.9) |
| *BRAF* V600E mutation | 5 (3.8) |
| *TYMS* LOH | 34 (26.2) |
| Overall survival |  |
| Deaths, *n* (%) | 45 (34.6) |
| Mean time in mo (95% CI) | 110.0 (99.5-120.5) |
| Disease-free survival |  |
| Events *n* (%) | 51 (39.2) |
| Mean time in mo (95% CI) | 100.1 (88.3-112.0) |
| Median follow up in mo (range) | 71.2 (0.5-156.8) |

AJCC: American Joint Committee on Cancer 7th edition; *TYMS*: Thymidylate synthase gene; LOH: Loss of heterozygosity; CI: Confidence interval.

**Table 3 Frequency of *TYMS* 5’ UTR, 3’ UTR genotypes**

|  |  |
| --- | --- |
| **Genotype** | **Total, *n* (%)** |
| *TYMS* 5’ UTR | 130 (100) |
| 2R | 13 (10.0) |
| 2R/3R | 78 (60.0) |
| 2R/3RG | 34 (26.1) |
| 2R/3RG | 20 (15.4) |
| 2R/3RGLOH | 8 (6.2) |
| 2RLOH/3RG | 6 (4.6) |
| 2R/3RC | 44 (33.8) |
| 2R/3RC | 24 (18.5) |
| 2R/3RCLOH | 13 (10.0) |
| 2RLOH/3RC | 7 (5.4) |
| 3R | 39 (30.0) |
| 3RG | 10 (7.7) |
| 3RG/3RC | 20 (15.4) |
| 3RC | 9 (6.9) |
|  |  |
| *TYMS* 3’ UTR | 130 (100) |
| ins/ins | 28 (21.5) |
| ins/LOH | 27 (20.8) |
| ins/del | 52 (40.0) |
| del/LOH | 7 (5.4) |
| del/del | 16 (12.3) |

*TYMS*: Thymidylate synthase gene; UTR: Untranslated region; SNP: Single nucleotide polymorphism; LOH: Loss of heterozygosity.

**Table 4 Associations between patient characteristics and *TYMS* polymorphisms**

|  |  |  |  |
| --- | --- | --- | --- |
| **Patient characteristics** | **Polymorphisms** | **RR (95% CI)** | ***P* value** |
| Birth after 1942 | 3RG/3RG | 5.128 (1.131-23.26) | 0.025 |
|  | 3RC/3RC and 3RC/LOH | 0.296 (0.088-0.988) | 0.035 |
| Male | 3RG/3RG and 3RG/LOH | 4.519 (1.072-19.06) | 0.030 |
| Grade III-IV | 3RG/3RC | 2.646 (1.167-6.024) | 0.022 |
| Stage III | 3RG/3RG and 3RG/3RC and 3RG/LOH | 2.198 (1.126-4.292) | 0.020 |
|  | 3RG/3RC | 4.149 (1.280-13.51) | 0.008 |
|  | Without any 3RG allele | 0.733 (0.546-0.984) | 0.050 |
|  | 3RC/3RC and 3RC/LOH | 0.333 (1.229-0.904) | 0.030 |
|  | 3RC/LOH | 0.122 (0.015-0.986) | 0.045 |
| *KRAS* mutation | 3RG/3RC | 3.135 (1.344-7.299) | 0.010 |
|  | 3RC/3RC and 3RC/LOH | 0.241 (0.057-1.015) | 0.030 |

*TYMS*: Thymidylate synthase gene; RR: Relative risk; CI: Confidence interval; LOH: Loss of heterozygosity.

**Table 5 Univariate Cox regression analysis for clinicopathological features and genotypes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **DFS** |  |  |  | **OS** |  |
| **Variable** | **HR** | **95% CI** | ***P* value** |  | **HR** | **95% CI** | ***P* value** |
| Age < 65 yr | 1.513 | 0.873-2.621 | 0.140 |  | 1.229 | 0.682-2.213 | 0.492 |
| Rectal Ca | 1.550 | 0.890-2.703 | 0.121 |  | 1.282 | 0.713-2.306 | 0.406 |
| Stage III *vs* I&II | 2.532 | 1.368-4.695 | 0.003 |  | 1.877 | 1.009-3.494 | 0.047 |
| Grade III&IV *vs* I&II | 1.984 | 1.143-3.436 | 0.015 |  | 2.097 | 1.166-3.770 | 0.013 |
| *KRAS* mutation | 1.330 | 0.761-2.326 | 0.321 |  | 1.283 | 0.702-2.346 | 0.418 |
| *BRAF* V600E mutation | 1.276 | 0.310-5.255 | 0.736 |  | 2.743 | 0.845-8.902 | 0.093 |
| *TYMS* 5’ UTR |  |  | 0.397 |  |  |  | 0.766 |
| 2R | 1 |  |  |  | 1 |  |  |
| 2R/3R | 1.213 | 0.498-2.958 | 0.671 |  | 0.745 | 0.332-1.672 | 0.475 |
| 3R | 1.690 | 0.678-4.213 | 0.260 |  | 0.846 | 0.355-2.020 | 0.707 |
| *TYMS* 5’ UTR |  |  | 0.596 |  |  |  | 0.615 |
| 2RG/3RG | 1 |  |  |  | 1 |  |  |
| 2RG/2RG | 1.038 | 0.377-2.858 | 0.942 |  | 1.750 | 0.672-4.559 | 0.252 |
| 2RG/3RC | 1.523 | 0.684-3.394 | 0.303 |  | 1.625 | 0.702-3.760 | 0.257 |
| 3RC/3RC | 1.414 | 0.482-4.148 | 0.528 |  | 0.680 | 0.146-3.162 | 0.623 |
| 3RG/3RC | 2.128 | 0.902-5.018 | 0.085 |  | 1.782 | 0.686-4.625 | 0.235 |
| 3RG/3RG | 1.489 | 0.466-4.672 | 0.502 |  | 1.996 | 0.610-6.532 | 0.253 |
| *TYMS* 5’ UTR |  |  | 0.204 |  |  |  | 0.589 |
| 2RG/3RG | 1 |  |  |  | 1 |  |  |
| 2RG/2RG | 1.702 | 0.343-8.441 | 0.515 |  | 3.322 | 0.787-14.03 | 0.102 |
| 2RG/3RC | 2.935 | 0.778-11.08 | 0.112 |  | 3.034 | 0.803-11.46 | 0.102 |
| 2RG/3RCLOH | 5.387 | 1.427-20.34 | 0.013 |  | 3.879 | 0.967-15.56 | 0.056 |
| 2RG/3RGLOH | 2.138 | 0.431-10.60 | 0.352 |  | 2.026 | 0.408-10.06 | 0.388 |
| 2RGLOH/3RC | 3.178 | 0.640-15.78 | 0.157 |  | 3.109 | 0.626-15.44 | 0.165 |
| 2RGLOH/3RG | 7.402 | 1.648-33.24 | 0.009 |  | 6.127 | 1.358-27.64 | 0.018 |
| 3RC/3RC | 4.326 | 1.031-18.15 | 0.045 |  | 1.733 | 0.288-10.42 | 0.548 |
| 3RG/3RC | 4.865 | 1.336-17.72 | 0.016 |  | 3.438 | 0.888-13.32 | 0.074 |
| 3RG/3RG | 3.413 | 0.761-15.30 | 0.109 |  | 3.994 | 0.887-17.99 | 0.071 |
| *TYMS* 5’ UTR groups |  |  | 0.130 |  |  |  | 0.223 |
| A1 | 1.136 | 0.574-2.251 | 0.714 |  | 1.882 | 0.917-3.861 | 0.085 |
| B2 | 1 |  |  |  | 1 |  |  |
| C3 | 1.908 | 0.980-3.713 | 0.057 |  | 1.309 | 0.637-2.692 | 0.464 |
| *TYMS* 3’ UTR |  |  | 0.791 |  |  |  | 0.846 |
| del/del | 1.170 | 0.496-2.760 | 0.721 |  | 1.145 | 0.456-2.873 | 0.773 |
| ins/del | 1.244 | 0.664-2.329 | 0.495 |  | 1.219 | 0.622-2.387 | 0.564 |
| ins/ins | 1 |  |  |  | 1 |  |  |
| *TYMS* 3’ UTR |  |  | 0.299 |  |  |  | 0.391 |
| del/del | 0.624 | 0.244-1.595 | 0.324 |  | 0.634 | 0.228-1.761 | 0.382 |
| del/LOH | 0.374 | 0.086-1.630 | 0.190 |  | 0.408 | 0.093-1.797 | 0.236 |
| ins/del | 0.634 | 0.329-1.224 | 0.175 |  | 0.743 | 0.372-1.482 | 0.399 |
| ins/LOH | 1 |  |  |  | 1 |  |  |
| ins/ins | 0.417 | 0.172-1.016 | 0.054 |  | 0.391 | 0.140-1.087 | 0.072 |
| ins/ins *vs* ELSE | 0.593 | 0.267-1.318 | 0.200 |  | 0.511 | 0.201-1.297 | 0.158 |
| ins/LOH *vs* ELSE | 1.807 | 1.000-3.266 | 0.050 |  | 1.650 | 0.877-3.104 | 0.120 |
| ins/del *vs* ELSE | 0.976 | 0.556-1.713 | 0.933 |  | 1.131 | 0.626-2.044 | 0.684 |
| del/del *vs* ELSE | 0.964 | 0.411-2.262 | 0.934 |  | 0.907 | 0.358-2.299 | 0.837 |
| del/LOH *vs* ELSE | 0.565 | 0.137-2.327 | 0.430 |  | 0.570 | 0.138-2.359 | 0.438 |
| LOH | 1.480 | 0.833-2.629 | 0.181 |  | 1.350 | 0.732-2.487 | 0.336 |
| SNP G->C | 1.542 | 0.878-2.707 | 0.132 |  | 1.108 | 0.617-1.992 | 0.731 |

1Low expression profile; 2Medium expression profile; 3High expression profile. DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; Ca: Cancer; *TYMS*:Thymidylate synthase gene; UTR: Untranslated region; LOH: Loss of heterozygosity; 5FU: 5-fluorouracil; SNP: Single nucleotide polymorphism.

**Table 6 Multivariate Cox regression analysis for clinicopathological features and selected genotypes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **DFS** |  |  | **OS** |  |
| **Variable** | **HR** | **95% CI** | ***P* value** | **HR** | **95% CI** | ***P* value** |
| Stage III *vs* I & II | 2.432 | 1.279-4.625 | 0.007 |  |  |  |
| Grade III & IV *vs* I & II | 1.715 | 0.951-3.091 | 0.073 | 1.860 | 0.982-3.525 | 0.057 |
| *TYMS* 5’ UTR groups |  |  | 0.031 |  |  | 0.052 |
| A | 3.122 | 1.193-8.169 | 0.020 | 2.715 | 1.093-6.739 | 0.031 |
| B | 1 |  |  | 1 |  |  |
| C | 2.919 | 1.258-6.772 | 0.013 | 2.540 | 1.098-5.876 | 0.029 |
| *TYMS* 3’ UTR groups |  |  |  |  |  |  |
| A (without ins/LOH) | 1 |  |  |  |  |  |
| B (ins/LOH) | 4.124 | 1.744-9.753 | 0.001 | 3.335 | 1.474-7.548 | 0.004 |
| *BRAF* V600E mutation |  |  |  | 4.500 | 1.241-16.32 | 0.022 |

DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; *TYMS*: Thymidylate synthase gene; UTR: Untranslated region; LOH: Loss of heterozygosity.